Glooko has implemented a dosing regulation feature in their app for T2 diabetics on long acting insulin.
Glooko’s Mobile Insulin Dosing System (MIDS) was cleared Wednesday for the titration of long-acting insulin by the FDA.
4 Likes
@docslotnick, the link wasn’t coming through so I edited it.
This article is quite interesting: the way I read it, the app has an algorithm that proposes an MDI basal level for a given BG meter pattern.
The article specifies T2s as the target. I am not 100% sure if it simply does not apply to T1s, or if it was only tested on T2s.
Thank you @Michel. I must have copy/pasted incorrectly.
From what I can discern is that the FDA approval is only for T2’s. Don’t injure much beyond that.
1 Like
This article seems to suggest that it is only for T2s on basal insulin only using a long acting.
It claims it will make dosing suggestion based a doctors plan and fasting BG readings. This seems like a tall order to me. Fasting readings only tell part of the story. Color me skeptical until I see more information.
2 Likes
I am intrigued, though. I would like to see what it comes up with.
But I also am skeptical. Yet it might be better than what some uneducated PWDs may come up with on their own?